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CHAPTER I 
INTRODUCTION 
The role of dopamine (3,4, dihydroxyphenethylamine) as an important 
central neurotransmitter agent has been acknowledged for some time 
(27). It has only been in recent years, however, that the possibility 
of a peripheral action of this catecholamine in the functional regu-
lation of various organ systems has been given serious consideration, 
and Goldberg (15) has proposed a specific role for this agent in the 
control of the vascular dynamics of the kidney. A number of electron 
microscopic and fluorescent studies (2, 3, 28, 44) in this organ have 
shown that there is a direct secretomotor innervation by the sympa-
thetic nervous system of the juxtaglomerular cells of the afferent 
arteriole. These cells are involved in the synthesis and secretion 
of the peptide hormone, renin. Norepinephrine is the neurotransmitter 
secreted by these sympathetic nerve terminals, and various studies 
have indicated that this catecholamine may exert a direct stimulatory 
control on renin secretion through a beta-adrenergic receptor mechan-
ism, which utilizes cAMP as the intracellular mediator (8, 13, 31). 
Some investigators (8, 23) have also recently postulated an inhibitory 
role for norepinephrine on renin secretion, which appears to be medi-
ated by alpha-adrenergic receptors. The significance of the apparent 
dual regulation of renin secretion by this catecholamine is unclear. 
Despite the known importance of dopamine as a central nervous 
system neurotransmitter, no attempts have been made to investigate the 
possibility of renal dopaminergic nerve terminals participating in 
the regulation of renin secretion, as well as to examine whether or 
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not dopamine itself may be released from adrenergic nerve terminals 
to exert its effect, since it is a direct precursor of norepinephrine. 
Only two in vitro studies (18, 24) have addressed this question, and 
the data suggests that dopamine may directly stimulate renin secretion 
from rat renal cortical slices although the nature of the receptors 
or mechanisms involved remain unclear. 
In a review by Goldberg (15) a number of physiological actions 
mediated by dopamine have been examined. This investigator suggests 
that the diversity of effects of this catecholamine on various organ 
tissues may be explained on the basis of the structure of the mole-
culte itself, namely that the catecholamine head and flexible side 
chain have the structural capability of binding to various types of 
membrane receptors. This would certainly support the view that dopa-
mine is capable of exerting a direct action on a given organ cell. 
The data of Henry and co-workers (18) appear indicative of such a 
direct influence of dopamine on the renal renin-secretory cells. 
Furthermore, preliminary studies in our own lab (23) suggest not 
only that dopamine directly stimulates renin secretion from the 
juxtaglomeurlar cells, but that this effect may be mediated by intra-
cellular cAMP changes. 
Although the previously cited studies implicate dopamine itself 
as having a direct effect on renin secretion, the possible conversion 
of dopamine to norepinephrine in the tissue preparation constitutes 
a factor which can not be overlooked. The use of a dopamine beta-
hydroxylase inhibiting agent such as FLA-63 (5, 37) in in vitro 
studies would eliminate this possibility. A number of in vivo and in 
vitro studies have shown FLA-63 to be an effective inhibitor of 
dopamine beta-hydroxylase at a range of concentrations in various 
tissues (5, 7). 
3 
In order to eliminate in vivo humoral and hemodynamic influences 
on renin secretion this investigation will utilize a hypersensitive 
renal cortical slice preparation from rats maintained on a sodium-
deficient diet for 1.5 to 2.5 weeks. Lopez and co-workers (23) have 
confirmed previous in vivo work indicating that dietary sodium defi-
ciency potentiates the renin secretory response to sympathetic stimuli. 
The hypersensitive in vitro kidney slice preparation is an ideal 
tool to more effectively evaluate not only positive, but as importantly 
negative renin release responses to dopamine and various receptor 
blockers, respectively. 
Therefore, the purpose of the present study is: (1) to evaluate, 
utilizing an in vitro rat renal cortical slice preparation, a possi-
ble direct stimulatory role of dopamine itself on the renin-secreting 
juxtaglomerular cells of the kidney, when added either alone or in 
conjunction with the specific dopamine receptor blocking agent, pimo-
zide; (2) to examine the possibility that dopamine may partially exert 
its influence on renin secretion through a beta-adrenergic receptor 
mechanism, by the use of the beta-receptor blocker propranolol; and 
(3) to elucidate whether or not cAMP is involved as an intracellular 
mediator of the renin secretory response to added dopamine. 
CHAPTER II 
REVIEW OF LITERATURE 
During the past ten years a number of important effects of 
dopamine on peripheral organ tissue function have been proposed. 
Dopamine has been shown to exert a number of effects in the cardiovas-
cular system (17, 34, 35, 40), some of which appear to be mediated 
by a beta-adrenergic receptor mechanism since the specific beta-
adrenergic blocking agent propranolol inhibits the stimulatory effect 
of dopamine on heart rate and cardiac contractility. As suggested 
by Goldberg (15), these observations support the concept that dopamine 
can effectively bind to membrane receptors other than specific dopa-
mine-sensitive receptors. This possibility is further supported by 
examining the effects of dopamine on blood vessels. Goldberg (17) and 
others (26, 35) have shown that dopamine infusion can stimulate the 
contractility of both arteries and veins. These actions can be ef-
fectively blocked by high concentrations of phenoxybenzamine, an alpha-
adrenergic receptor blocker, which suggests that dopamine influences 
vascular contractility through an alpha-adrenergic receptor mechanism. 
Dopamine also appears to be involved in the relaxation and vaso-
dilation of vascular tissue through reflex and neurogenic mechanisms. 
This influence appears to be exerted by an action on beta-adrenergic 
receptors. In this regard, McNay and Goldberg (26) have demonstrated 
that after phenoxybenzamine administration dopamine infusion causes 
vasodilation in the skeletal muscle vascular bed of the dog. Further-
more, Kohli (22) has shown that relaxation occurs in the isolated aortic 
strip under similar conditions. Propranolol antagonism of these 
4 
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actions suggests a dopamine-induced vasodilating mechanism exerted 
through a beta-adrenergic receptor. Conversely, propranolol antagon-
ism may not be due to beta-adrenergic receptor involvement but rather 
to alpha vasoconstricting activity (32). This view has been supported 
by Goldberg and colleagues, who have shown that high concentrations of 
propranolol do not alter dopamine-induced relaxation of isolated canine 
renal, mesenteric, coronary or femoral arteries (39). 
These conflicting observations have led to the postulation of 
an alternative mechanism of action of dopamine on smooth muscle vascu-
lature which involves a direct interaction with specific dopamine 
vascular receptors (25). In one such study, administration of phenoxy-
benzamine to an anesthesized dog, followed by an intra-arterial infu-
sion of dopamine resulted in vasodilation of the renal and mesenteric 
vascular beds in a dose-related fashion (17). This vasodilating 
effect could not be decreased by propranolol, atropine, anti-histamine 
or by pretreatment with reserpine, 48/80, or monoamine oxidase 
inhibitors (17). Similar results have been observed by investigators 
examining other vascular structures (34, 43). 
The observations that dopamine causes renovascular dilation 
through an apparent specific dopaminergic receptor has stimulated 
the study of the role of this agent in blood pressure control and 
renin secretion. Most data in this regard have been obtained from 
studies performed in vivo utilizing dogs or human subjects. Ayers 
and co-workers (1) have shown that dogs, made hypertensive by right 
nephrectomy and partial occlusion of the left renal artery, exhibit 
chronic elevation of blood pressure but renin secretion remained 
normal. They demonstrated that infusion of the vasodepressor drugs 
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reserpine, hydralazine, and trimethophan did not produce significant 
increases in renin release. Conversely, infusion of isoproterenol 
lowered the blood pressure and produced a marked stimulation of renin 
release. On the other hand, the same investigators observed a marked 
increase in renin secretion following dopamine infusion in reno-vascu-
lar hypertension, in the presence of decreased, normal, or elevated 
arterial blood pressures. They concluded that it was not a blood 
pressure change but rather vasodilation that was important in stimulat-
ing renin release. 
A number of other investigators, working in vivo have also shown 
that dopamine stimulates renin release. In a series of experiments, 
Bell and Lang (4) selectively initiated hemmorhage or acute suprarenal 
aortic stenosis in mongrel dogs, and measured plasma angiotensin II 
levels as an index of changes in renin secretion. Under these condi-
tions, infusion of dopamine resulted in increased angiotensin II levels 
in both the hemmorhaging and ischemic groups. This increase was 
effectively blocked by the dopamine receptor antagonist, ergometrine. 
From these data, they concluded that stimulation of renin release is 
exerted through dopaminergic nerves, although the mechanisms involved 
are unclear. 
Cuche and co-workers (11) have examined the involvement of dopamine 
in regard to the effects of posture changes in humans. It has already 
been established that changing from the supine to upright posture in 
humans stimulates the sympathetic nervous system (21). In their 
studies, they found that upon changing from the supine to the upright 
position, plasma renin activity increased, urinary dopamine concentra-
tion decreased, urinary norepinephrine concentration increased, and 
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urinary sodium concentration decreased. From these data Cuche and 
his group proposed a number of possible effects of dopamine on renin 
secretion. Since dopamine possesses some alpha-adrenergic action but 
little or no beta-adrenergic activity its inhibitory effect on renin 
release may be mediated by either a specific dopaminergic receptor 
or alternatively by competing with norepinephrine at the receptors of 
the juxtaglomerular cells. Therefore, each catecholamine could con-
ceivably have an affect on renin-secretion through a direct action on 
the renin secreting cells. Cuche and co-workers (11) have alternative-
ly suggested that dopamine may affect renin secretion through its 
effect on sodium excretion. This appears to be an indirect inhibitory 
effect on renin release through increases in sodium load at the 
macula densa. Furthermore, they have indicated that dopamine action 
could also be mediated by renal blood flow-dependent pressure changes 
at the juxtaglomerular cells, since dopamine inhibits plasma renin 
activity under conditions of low renal plasma flow (11). This action 
may be mediated by the afferent arteriole baroreceptors. Wilcox and 
his group (46) have also compared the effects of dopamine and norepi-
nephrine on renin release in human subjects. They observed that 
plasma renin activity was increased with dopamine infusion. Plasma 
renin activity decreased with equipressor doses of norepinephrine. 
These data, although in disagreement with previous data suggesting an 
inhibitory role of dopamine on renin release, may actually support the 
view that it is the activation of specific dopaminergic receptors which 
mediate the effect of dopamine on renin secret~on. 
Additional studies by Chokshi and colleagues (9), have done little 
/ 
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to further clarify whether or not dopamine is directly stimulatory or 
inhibitory to renin secretion. In these studies dopamine and isopro-
terenol were alternately infused into the renal artery of adult dogs. 
Under these conditions, it was found that dopamine increased renal 
blood flow and decreased renin secretion, while isoproterenol increased 
both parameters. Propranolol treatment prior to dopamine infusion 
did not alter the response in renal blood flow or renin secretion. 
Infusion of propranolol prior to isoproterenol blocked the increase 
in renin secretion with no change in renal blood flow. The results 
seen with dopamine in these studies can be explained by the known 
vasodilating properties of dopamine on the renal vasculature which 
would cause a decrease in renin release. This would be considered an 
indirect effect rather than a direct one on the juxtaglomerular cells. 
Most in vivo studies evaluating the possibility of a direct ef-
feet of dopamine on renin release have produced inconclusive data, 
perhaps because of the variety of factors interrelating in the live 
animal to influence secretion of this hormone. The possible mechanism 
and site of action of dopamine have therefore, remained largely un-
clear. Recently, however, a few in vitro studies have been more pro-
mising in this regard, primarily because this type of preparation 
effectively eliminates humoral, hemodynamic and other in vivo influences 
which are known to affect renin release. 
Nakajimaand colleagues (29) have shown that addition of dopamine 
to an in vitro rat kidney particulate preparation produced significant 
increases in the cAMP content of the tissue. This increase in the 
/ 
tissue nucleotide concentration was not affected by simultaneous addi-
tion of either the adrenergic blocker, phentolamine, or the beta-
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adrenergic blocker, propranolol. This suggests the involvement of 
an alternative type of receptor. Addition of spiroperidol, a speci-
fic dopamine-receptor antagonist, effectively blocked the increase in 
tissue cAMP by dopamine, whereas, apomorphine, an analog of dopamine, 
increased tissue cAMP content when added to the preparation. From 
these observations, Nakajima and co-workers concluded that the increase 
in cAMP produced by the addition of dopamine constitutes evidence 
for the existence of a cAMP mediated dopamine-receptor mechanism in 
renal vascular tissue. This view is consistent with the existence 
of a dopamine-sensitive adenylate cyclase mechanism in the mammalian 
brain and retina (6, 10, 20). 
In a follow-up study, Nakajima and co-workers (30) perfused an 
isolated rat kidney with various reagents. Perfusion with dopamine 
resulted in a significant increase in cAMP concentration in the per-
fusate. The increase in the concentration of this nucleotide was 
potentiated by theophylline, a phosphodiesterase inhibitor, and con-
sistently blocked by spiroperidol, a dopamine-receptor blocking agent. 
They also observed that the stimulatory effect of dopamine on cAMP 
concentration was very rapid, an observation which is consistent 
with the proposed mechanism of action of receptors which utilize cAMP 
as an intracellular mediator. Nakajima and colleagues (29) have 
suggested that dopamine acts through a specific dopamine receptor 
located on the vascular tissue of the rat kidney to produce vasodila-
tion. This view agrees with the concept of a renal vascular receptor 
proposed by Yeh, McNay and Goldberg (42). 
In contrast, Henry and co-workers (18) utilizing an in vitro rat 
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renal cortical slice preparation, have recently evaluated the possi-
bility of a direct effect of dopamine on renin secretion. Addition of 
dopamine at concentrations greater than 10-5 M resulted in significant 
increases in renin release, an observation which suggests a direct 
effect of this amine on the juxtaglomerular cells. Moreover, pheni-
prazine, a monoamine oxidase inhibitor, potentiated the rate of renin 
release. In the same studies, simultaneous addition of phentolamine 
(an alpha--adrenergic receptor blocker), haloperidol (a dopamine-recep-
tor blocker), or cocaine (a catecholamine uptake inhibitor) did not 
affect the stimulatory effect of dopamine on renin release. However, 
the addition of propranolol, a beta-adrenergic receptor blocker, signi-
ficantly inhbited the stimulatory effect of dopamine on renin secretion. 
From these observations, Henry and colleagues concluded that dopamine 
may directly influence renin release from the juxtaglomerular cells 
via a beta-adrenergic receptor mechanism most likely located on the 
membranes of those cells, rather than by a dopamine-sensitive receptor 
pathway. 
Recent studies in our laboratory (24) have supported Henry's ob-
servation of a direct stimulatory effect of dopamine on renin secre-
tion. We further extended their findings by clearly showing a positive 
correlation between the renin secretory responses and the changes in 
tissue cAMP content. This constitutes additional evidence for the 
existence of a cAMP·-mediated receptor mechanism by which dopamine 
may directly influence renin release. Additionally, it has been 
shown (24) that pimozide, a dopamine receptor blocking agent, effec-
tively prevents the stimulatory effect of dopamine on renin release. 
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This observation is not in agreement with Henry's, but supports the 
concept of a dopamine-sensitive receptor mechanism mediating the 
stimulation of renin secretion by dopamine. 
It is obvious from the data reviewed here, that additional 
studies are needed to further examine the possibility that this impor-
tant central nervous system neurotransmitter may play a significant 
regulatory role in the control of renin secretion, and thus, may 
participate in the regulation of extracellular fluid volume, electro-
lyte, and blood pressure homeostasis. 
CHAPTER III 
MATERIALS AND METHODS 
Thirty-six male, Sprague-Dawley rats (Madison, Wisconsin), with 
initial weights of 210 ± 10 gm were fed a sodium-deficient diet, (Teklad 
Test Diets, Madison, Wisconsin), which provided less than 0.02 ~g of 
sodium per day, for a period of 10 to 17 days. The rats were kept two 
animals per cage, in a temperature-controlled room (23 ± 20 C) with a 
12 hour light/12 hour dark photoperiod. The rats had access to dis-
tilled, deionized water ad libitum. After 10 to 17 days on the diet, 
the animals were decapitated and their kidneys rapidly excised. The 
kidneys were then placed in Robinson's buffer medium at 4° C (12), 
gassed for 30 seconds with a mixture of 95% oxygen - 5% carbon dioxide, 
decapsulated, and gassed a second time. Renal cortical slices approxi-
mately 0.3 mrn thick and weighing 50 ± 20 mg were subsequently prepared 
using a Stadie-Rigg's microtome (A.H. Thomas, Co.). 
Each slice was divided into several similar sections, which were 
randomly assigned to seven incubating vessels containing 2.5 ml Robinson's 
buffer medium at 4° C. Renal slices from other areas of the cortex 
were similarly prepared until each incubating vessel contained 50 ± 
20 mg of renal cortical tissue. The slices were then preincubated 
for 15 minutes at 37° C in a shaking Dubnoff Metabolic Incubator 
(Precision Scientific Cn), in a humidified atmosphere of 95% oxygen 
5% carbon dioxide. After preincubation, the slices were transferred 
to matching vessels containing fresh Robinson's buffer medium at 37° C 
and were subsequently incubated for one hour under conditions identical 
12 
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To those during preincubation. One of each group of seven paired 
vessels served as an untreated control. The other six vessels con-
taining the tissue slices received 10-3 M dopamine (Sigma Chemical 
Co.) added alone or in conjunction with lo-4 M of the beta-receptor 
blocking agent, propranolol (Sigma Chemical Co.), or one of three 
doses (10-? M, 10-6M, 10-5 M), of the dopaminergic receptor blocking 
agent, pimozide (Janssen Pharmaceutical). Propranolol and pimozide 
were also added alone to the slice preparation. The dopamine beta-
hydroxylase inhibitor, FLA-63 (10-4 M) (Regis Chemical Co.) was added 
in conjunction with the experimental agents in all instances in order 
to inhibit the conversion of dopamine to norepinephrine. Control tis-
sue was incubated in the presence or absence of FLA-63. The antagonis-
tic agents and FLA-63 were added to the slice preparation in both the 
preincubation and incubation periods, whereas dopamine was added only 
in the incubation media. Dopamine and FLA-63 were prepared in a 
0.1% ascorbic acid solution (Sigma Chemical Co.) to prevent oxidation 
(45). Pimozide was prepared in 1.2% tartaric acid (Fisher), also to 
prevent oxidation. Propranolol was dissolved in Robinson's buffer 
medium. After incubation, the supernatant medium was collected and 
stored at -20° C until assayed for renin concentration by radioimmuno-
assay of angiotensin I. The renal tjssue was immediately frozen on 
dry-ice and homogenized in l ml of 8% trichloracetic acid (Mallinkrodt). 
The tissue homogenates were transferred to 12 x 75 mm pyrex tubes 
(Scientific Products), containing five drops of 0.1 N HCl, vortexed, 
and frozen at -200 C until assayed for cAHP content. 
A. Renin Concentration Determination by Radioimmunoassay Angiotensin I 
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1. Angiotensin I Generation 
Since no direct assay exists for renin, renin concentration was 
measured by determining the rate of Angiotensin I formation in the pre-
sence of exogenous renin substrate (angiotensinogen). This was follow-
' 
ed by radioimmunoassay measurement of the Angiotensin I generated, 
which is proportional to the amount of renin present. To generate 
Angiotensin I, the supernatant samples were thawed, vortexed for ten 
seconds and maintained in a water bath at 40 C. Aliquots of 25 ~1 
from each sample were transferred to 12 x 75 mm tubes and kept at 4° 
C. Five drops of saturated NaCl, and 0.5 ml of 24-hour nephrectomized 
dog plasma, containing renin substrate (angiotensinogen) were then 
added to each tube. The nephrectomized plasma had previously been 
treated with a 1% phenylmethylsulfonylflouride (PMSF) solution (0.05 ml 
of PMSF/ml of plasma) to inhibit the action of converting enzyme and 
other angiotensinases present in plasma. Thus, the degradation of 
generated Angiotensin I or the conversion of Angiotensin I to Angio-
tensin II was prevented. The PMSF treated nephrectomized dog plasma 
was then incubated for two hours at 37° C, followed by a 1:2 dilution 
with distilled, deionized water. The samples were then vortexed, 
covered with aluminum foil to prevent evaporation, and placed in a 
boiling water bath for 2-3 minutes to stop further Angiotensin I gen-
eration. The samples were allowed to cool to room temperature, covered 
with parafilm, and stored at -20° C until assayed for Angiotensin I 
content by radioimmunoassay. 
2. Radioimmunoassay of Angiotensin I 
Renin concentration in the unknown samples was determined by 
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radioimmunoassay of the generated Angiotensin I, utilizing as trace, 
radioiodinated Angiotensin I (125I-Angiotensin I) and buffer solutions 
from the Squibb Company (Rolling Meadows, IL) and an Angiotensin I 
antibody (38) generously donated by Dr. Ian Reid (University of 
California at San Francisco). The results were expressed as nanograms 
of Angiotensin I generated per mg of wet tissue per hour. 
B. Determination of Cyclic 3'-5' Adenosine Monophosphate (cAMP) by 
Competitive Protein Binding Assay 
1. cAMP Extraction 
Frozen tissue homogenates were allowed to thaw and then centrifuged 
at 4000 rpm for ten minutes at 4° C. The supernatant was transferred 
to conical centrifuge tubes using Pasteur pipets (Sargent-Welch) and 
the protein precipitate discarded. Two ml of water-saturated ether 
(Mallinkrodt) were then added to each sample, vortexed, and the ether 
phase was aspirated and discarded using Pasteur pipets. This procedure 
was repeated three times. After the fourth wash, the cAMP-containing 
water phase was decanted into glass vials and immediately frozen on 
dry-ice. The frozen samples containing the water-soluble cAMP were 
subsequntly lyophilized and the freeze-dried cAMP was then stored.at 
-200 C until assayed. 
2. Competitive Protein Binding Assay for cAMP 
Cyclic AMP content of the tissue slices was determined by a 
modification of the protein-binding assay of Gilman (14). The results 
were expressed as picomoles of cAMP per mg of wet tissue. 
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C. Calculations 
Statistical significance of the various parameters studied was 
evaluated by modified paired and unpaired students "t" tests (36) 
using a programmable desk top calculator (Hewlett-Packard 9100B) at 
Argonne National Laboratory (Argonne, IL). 
CHAPTER IV 
RESULTS 
In an initial study the effect of the dopamine-beta-hydroxylase 
inhibitor, FLA-63 (lo-4 M) on the basal renin release and cAMP content 
of rat renal cortical slices from sodium-deficient rats was examined. 
There were no significant differences in either renin release or cAMP 
content between non-treated {control) or FLA-63 treated tissue. The 
mean change in renin release from control for tissue treated with 
FLA-63 was -0.023 ± 0. 25 ng/mg wet tissue/hour (P > 0. 05). The mean 
changes in cAMP content from control was 0.0009 ± 0.009 pmole/mg wet 
tissue (P > 0. 05). Thus, FLA-63 was utilized in conjunction with 
other experimental agents in subsequent studies. 
Figure 1 shows the renin release and tissue cAMP content changes 
seen in renal cortical slices treated with 10-3 M dopamine alone or 
10-3 M dopamine added together with FLA-63. In both instances, dopa-
mine signficantly increased both renin release and the cAMP content 
of the tissue during a one hour incubation period. 
In another study the effect of a stimulatory dopamine dose (lo-3 M) 
on renin release was evaluated when the specific dopamine-receptor 
blocking agent, pimozide (10-6M), was added to the slice preparation 
in the presence or absence of FLA-63 (lo-4 M). These data can be 
seen in Figure 2. In the absence of FLA-63, pimozide blocked the 
stimulatory effect of lo-3 M dopamine on renin release in rat renal 
cortical slices from sodium-deficient rats. Pimozide added by itself 
also significantly inhibited renin release. In contrast, when pimozide 
17 
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Figure 1. 
-3 Effect of dopamine hydrochloride (10 M) on renin release and 
cAMP content of renal cortical slices from sodium-deficient rats, 
added to the preparation either alone or in the presence of FLA-63. 
The data represent the mean renin release change ± S.E. and the mean 
cAMP content change± S.E., respectively. The mean control (non-
treated) rate of renin release was 5.43 ± 0.19 ng/mg/hr wet tissue in 
preparations without FLA-63 and 7.04 ± 0.32 in preparations with FLA-63. 
The mean control cAMP content was 0.42 ± 0.02 pmole/mg wet tissue in 
preparations without FLA-63 and 0.32 ± 0.01 pmole/mg wet tissue in 
preparations with FLA-63 present. Incubation time was 60 minutes. 
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was added together with dopamine in the presence of FLA-63, it poten-
tiated the stimulatory effect of dopamine on renin release, an effect 
which was completely opposite to the inhibition on this parameter 
exerted by pimozide, when FLA-63 was absent from the preparation. 
Furthermore, when pimozide alone was added to the slice preparation 
in the presence of FLA-63, renin secretion was significantly stimulated 
in relation to control. 
When the data on renin release (Figure 2) are compared to those 
in cAMP content in response to the same doses of dopamine and pimozide, 
in the presence of added FLA-63 (Figure 3), a clear dissociation 
between renin release responses and cAMP content changes was apparent. 
Previously it had been observed that without FLA-63 in the incubation 
medium, pimozide added together with dopamine significantly decreased 
both renin release and tissue cAMP content below control levels. The 
inhibitory effect of pimozide on tissue cA}W content was maintained 
when FLA-63 was added to the tissue preparation (Figure 3), whereas 
it was significantly reversed in regard to renin release (Figure 2). 
Moreover, the tissue cAMP content was significantly depressed in 
response to pimozide added alone (Figure 3) whether or not FLA-63 
was present. 
Since pimozide added alone to the renal cortical preparation 
significantly influenced both renin release and tissue cAMP, further 
experiments were undertaken to find a pimozide dose which by itself 
would be ineffective in influencing these parameters. Various doses 
of pimozide (lo-7 M, lo-6 M, 10-5 M) were added to the slice prepara-
tion either alone or in conjunction with a stimulatory dopamine dose 
21 
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Figure 2 
Comparison of changes in renin release in response to dopamine 
hydrochloride (lo-3 M) added alone or together with 10-6 M pimozide 
to renal cortical slices of sodium deficient rats, with or without 
FLA-63 present in the incubating medium. The data represent the 
mean renin release change± S.E .. The mean control (non-treated) 
rate of renin release was 5.43 ± 0.19 ng/mg/hr wet tissue in pre-
parations without FLA-63 present and 7.04 ± 0.32 ng/mg/hr wet tissue 
in preparations with FLA-63. Incubation time was 60 minutes. 
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Figure 3 
Changes in renin release and cAMP content in response to 
dopamine hydrochloride (lo-3 M) added alone or together with 
10-6 M pimozide to renal cortical slices of sodium-deficient 
rats, with or without FLA-63 present in the incubating medium. 
The data represent the mean renin release change± S.E •. The 
mean control rate of renin release was 5.43 ± 0.19 ng/mg/hr wet 
tissue in preparations without FLA-63 and 7.04 ± 0.32 in pre-
parations with FLA-63. The mean control cAMP content was 0.42 ± 
0.02 pmole/mg wet tissue in preparations without FLA-63 and 
0.32 ± 0.01 in preparations with FLA-63 present. Incubation 
time was 60 minutes. 
CHANGE 
IN 
RENIN 
RELEASE 
{ng/mg/hr) 
CHANGE 
IN 
cAMP 
(pmol/mg) 
0 NO FLA-63 
[] + FLA-63 l1o-4MJ 
n=number of observations 
20.0 
10.0 
5.0 
5.0 
• 
r:w EJ 
•• 
DOP DOP 
1o-3M 1o-3M 
+ 
PIMO 
1o-6M 
• significantly different from control(p< .os) 
• • significantly different from control(p<.01) 
DOP= DOPAMINE 
PIMO= PIMOZIDE 
•• 
•• 
•• 
• 
- 0:25 t'jj'"jj7!1 n=25 8 n=71 [ill]. --CONTROL ::::::::::: 
... •• •• 
PIMO DOP DOP PIMO 
1o-6M 1o-3M 1o-3M 10-6M 
+ 
PIMO 
1o-6M 
TREATMENT 
24 
25 
(10-3 M). FLA-63 (10-4M) was present in all instances. As seen 
previously with lo-6 M pimozide (Figure 3), additional doses of this 
agent in the presence of FLA-63 significantly potentiated the stimu-
latory effect of 10-3 M dopamine on renin secretion (Figure 4). The 
three pimozide doses added by themselves were also capable of signifi-
cantly stimulating renin release. The stimulatory effect of each dose 
was not statistically different from the other two, an observation 
which suggests maximal potentiation at this range of pimozide 
concentrations. 
At the three concentrations used, pimozide significantly decreased 
cAMP content of the tissue preparation when added either alone or 
in conjunction with dopamine. These data on cAMP content are again 
similar to those observed in previous studies in the absence of FLA-63. 
Also as previously observed with lo-6 M pimozide in the presence of 
FLA-63, the additional pimozide doses, either alone or together with 
dopamine, produced a marked dissociation of the renin release and 
tissue cAMP responses. Furthermore, the inhibitory effect of all 
three pimozide doses on tissue cAMP content when added alone appeared 
maximal. 
Since dopamine may structurally be capable of binding to other 
types of receptors, an additional study was performed to explore 
this possibility. In these experiments (Figure 6), a stimulatory 
dose of dopamine (lo-3 M) was added alone or together with the beta-
adrenergic receptor blocker propranolol (10-4 M) to renal cortical 
slices from sodium-deficient rats. FLA-63 (lo-4 M) was also added in 
conjunction with all treatments. At the concentration used, propranolol 
26 
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Figure 4 
The effect of dopamine hydrochloride (10-3 M) when added 
alone or together with various doses of pimozide, on renin 
release from renal cortical slices from rats fed a sodium-
deficient diet for 10 to 17 days. FLA-63 was present in all 
preparations. The data represent the mean renin release change 
± S.E .. The mean control rate or renin release was 7.04 ± 0.32 
ng/mg/hr wet tissue and the mean control content of cAMP was 
0.32 ± 0.01 pmole/mg wet tissue. Incubation time was 60 minutes. 
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Changes in renin release and cAMP content in response to 
dopamine hydrochloride (lo-3 M) when added either alone or 
together with various pimozide concentrations to renal cortical 
slices of sodium-deficient rats. FLA-63 (10-4 M) was present in 
all preparations. The data represent the mean renin release 
change± S.E. and the mean cAMP content change± S.E •• The mean 
control rate of renin release was 7.04 ± 0.32 ng/mg/hr wet tissue 
and the mean control content of cAMP was 0.32 ± 0.01 pmole/mg 
wet tissue. Incubation times was 60 minutes. 
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effectively prevented the stimulatory effect of dopamine on renin 
secretion. Propranolol added by itself was ineffective. Similarly, 
propranolol effectively blocked the stimulatory effect of dopamine 
on tissue cAMP content seen previously. By itself, however, propranolol 
was also capable of inhibiting tissue cAMP content. 
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Figure 6 · 
Effect of dopamine hydrochloride (10-3 M) .on renin release 
and cAMP content, when added either alone or together with pro-
pranolol (10-4 M) to renal cortical slices of sodium-deficient 
rats. FLA-63 (lo-4 M) was present in all preparations. The data 
represent the mean renin release change ± S.E. and the mean cAMP 
content change± S.E .. The mean control rate of renin release 
was 7.04 ± 0.32 ng/mg/hr wet tissue and the mean control cAMP 
content was 0.32 ± O.Ol•pmole/mg wet tissue. Incubation was 
60 minutes. 
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CHAPTER V 
DISCUSSION 
The in vivo studies of Goldberg and colleagues (16, 26, 47) 
and the in vitro observations of Nakajima and co-workers (29, 30) 
have provided strong evidence pointing to the existence of specific 
dopaminergic receptors involved in the control of renal vascular 
dynamics. The postulated receptors appear to be located on the walls 
of the renal blood vessels. These vascular receptors may well exist, 
however, their existence does not rule out the possibility that 
a specific dopamine receptor may be located elsewhere in the kidney, 
subserving other functions, and perhaps renin secretion. Data from 
in vitro studies of Henry and his group (18) support the view that 
renal dopamine receptors may be located on the renin-secreting juxta-
glomerular cells. They propose that the stimulatory effect of dopa-
mine is mediated by a beta-adrenergic receptor mechanism, similar to 
that involved in mediating the action of other catecholamines, such 
as norepinephrine. Additional observations by Lopez and co-workers 
(23) support the concept that the effect of dopamine on renin secre-
tion may be directly exerted through a specific dopamine receptor 
located on the juxtaglomerular cells and that this receptor mechanism 
may be intracellularly mediated by cAMP changes. 
The present study further attempts to evaluate the possibility 
of a direct regulation of renin release by dopamine. FLA-63 (lo-4 M) 
by itself had no significant effect on resting renin release or 
cAMP content of the tissue. This is important since it essentially 
33 
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eliminates the possibility that the added FLA-63 affects either renin 
release or tissue cAMP content. Furthermore, in the presence of FLA-
63, dopamine (10-3 M) stimulates renin release and cAMP content 
simultaneously (Figure 1). Values for renin secretion and cAMP con-
tent were not statistically different from preparations in which dopa-
mine was added without FLA-63. These data suggest that a dopamine-
sensitive membrane receptor exists and that the stimulatory effect of 
dopamine on renin release may be mediated by increasing tissue c&~ 
content. 
In the presence of FLA-63, pimozide markedly potentiated the dopa-
mine stimulatory effect on release (Figure 2). This is in direct con-
trast to previous observations (23) that pimzoide blocked the stimula-
tory effect of dopamine on renin secretion when FLA-63 was absent 
from the incubation media. Pimzoide added alone to the slice prepar-
ation in the presence of FLA-63 also significantly increased renin 
release as opposed to its inhibitory effects when FLA-63 was not pre-
sent (23). Conversely, pimozide added either alone or in conjunction 
with a stimulatory dose of dopamine significantly inhibited tissue 
cAMP generation in relation to controls whether FLA-63 was present 
or not (Figure 3). This dissociation of the effects of pimozide on 
renin release and cAMP content of the tissue when FLA-63 is added to 
the preparation is not easily explained. One possible explanation is 
that dopamine, itself, may actually control renin secretion in an 
inhibitory manner through a specific dopamine receptor mechanism and 
that the addition of pimozide releases this inhibition. However, the 
simultaneous significant decrease in tissue cA}W by pimozide is not 
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consistent with this view. Alternatively, since pimozide by itself 
was capable of causing marked increases in renin release and decreases 
in tissue cAMP content it is possible that the observed responses are 
strictly due to a generalized membrane effect of this agent. The 
effect being uncontrolled renin release from the juxtaglomerular 
cells, despite inhibition of secretory mechanisms mediated by cAMP. 
This generalized membrane effect concept has previously been postu-
lated by Johns and co-workers (19) to explain the stimulatory influence 
of the synthetic catecholamine, isoproterenol, on renin secretion. 
It is also possible that pimozide and FLA-63 may interact in some 
manner to initiate these responses although the mechanism is unclear. 
Subsequent studies utilizing additional doses of pimozide, in 
the presence of FLA-63, largely confirmed the initial observations 
that pimozide added alone or together with dopamine, is capable of 
significantly potentiating renin release. At the three doses examined, 
pimozide appeared to exert maximal effects on both renin release and 
cAMP content since no significant differences were detected when the 
various responses were statistically compared. 
It is obvious from these data, that the question regarding the 
involvement of a dopamine-sensitive receptor in mediating the effect 
of dopamine on renin release can not be properly evaluated. It is 
necessary to find a dose of pimozide which, by itself, is ineffective 
in influencing both renin release and tissue cAMP content, as well as 
to examine other specific dopamine receptor blocking agents such as 
butaclamol. These data should be of great value in determine whether 
or not dopamine directly affects renin secretion through a specific 
dopamine-receptor pathway. 
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The observations of this study indicate that dopamine, by 
itself, is capable of significantly and simulatenously stimulating 
both renin release and tissue cAMP content, while the report of 
Henry and co-workers (18) suggests that this stimulatory effect may be 
mediated by a beta-adrenergic mechanism. To investigate the possibility 
that the renin-secretory responses to dopamine may be mediated by a 
beta-adrenergic mechanism a subsequent experiment utilized the speci-
fic beta-adrenergic receptor blocker, propranolol. In the presence 
of FLA-63 (10-4 M), propranolol (lo-4 M) effectively prevented the 
stimulatory effect of dopamine (lo-3 M) on renin secretion and cAMP 
content. Propranolol by itself had no effect on renin secretion, but 
it did inhibit tissue cAMP content. These data are consistent with 
the concept that the stimulatory effects of dopamine on renin secre-
tion may be at least partially mediated by a beta-adrenergic receptor 
mechanism. Goldberg (15) has reported that dopamine is capable of 
binding to receptors other than specific dopamine ones, due to its 
catechloamine head and flexible side chain. Additional studies are 
being designed to examine the possiblity of a partial dopaminergic 
regulation of renin secretion through renal alpha-adrenergic recep-
tors different from those known to mediate blood pressure changes 
in the renal vasculature. 
In summary, the data present here support the view that dopamine 
itself exerts a direct regulation of renin secretion from the juxta-
glomerular cells of the sodium-deficient rat. These results also sup-
port the view that this control of renin release by dopamine is partially 
exerted through a beta-adrenergic receptor mechanism which utilizes 
cAMP as the intracellular mediator. 
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However, the data have left unanswered the question as to 
whether or not the regulatory influence of dopamine on renin release 
is mediated by a specific dopamine-sensitive receptor mechanism. 
Studies designed to further evaluate this possibility, as well as 
the possibility that dopamine may partially regulate renin release 
through other receptor types, are clearly needed. 
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